Molecular Insight Pharmaceuticals has completed the previously announced purchase of a radiopharmaceutical manufacturing facility in Denton, TX.
A portion of the facility, which was purchased from NeoRx Manufacturing Group for $3 million, will initially be used to manufacture the company's Azedra lead-targeted molecular radiotherapeutic candidate, according to the Cambridge, MA-based firm. The facility should also be fully operational prior to the potential launch of the company's Zemiva molecular imaging agent, Molecular Insight said.
By AuntMinnie.com staff writers
October 3, 2007
Related Reading
Molecular Insight appoints CFO, August 16, 2007
Molecular Insight posts Q2 2007 results, August 13, 2007
Molecular Insight buys Texas radiopharma plant, May 18, 2007
Molecular Insight adds revenues in Q1, May 15, 2007
Molecular Insight prices IPO, February 2, 2007
Copyright © 2007 AuntMinnie.com
